Validating a Proteomic Signature of Severe COVID-19

COVID-19 is a heterogenous disease. Biomarker-based approaches may identify patients at risk for severe disease, who may be more likely to benefit from specific therapies. Our objective was to identify and validate a plasma protein signature for severe COVID-19. DESIGN: Prospective observational coh...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosgriff, Christopher V., Miano, Todd A., Mathew, Divij, Huang, Alexander C., Giannini, Heather M., Kuri-Cervantes, Leticia, Pampena, M. Betina, Ittner, Caroline A. G., Weisman, Ariel R., Agyekum, Roseline S., Dunn, Thomas G., Oniyide, Oluwatosin, Turner, Alexandra P., D’Andrea, Kurt, Adamski, Sharon, Greenplate, Allison R., Anderson, Brian J., Harhay, Michael O., Jones, Tiffanie K., Reilly, John P., Mangalmurti, Nilam S., Shashaty, Michael G. S., Betts, Michael R., Wherry, E. John, Meyer, Nuala J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722553/
https://www.ncbi.nlm.nih.gov/pubmed/36479446
http://dx.doi.org/10.1097/CCE.0000000000000800

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722553/
https://www.ncbi.nlm.nih.gov/pubmed/36479446
http://dx.doi.org/10.1097/CCE.0000000000000800

Ejemplares similares